NCT06074757View on ClinicalTrials.gov

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

September 10, 2023

Study Completion Date

October 1, 2023

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Fulvestrant injection

phosphate ester of fulvestrant for test arm

Trial Locations (1)

11941

Triumpharma Cro, Amman

Sponsors
All Listed Sponsors
lead

Kashiv BioSciences, LLC

INDUSTRY

NCT06074757 - Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study | Biotech Hunter | Biotech Hunter